Valuation: Alvotech

Market Cap 1.23B 1.08B 996M 923M 1.75B 117B 1.78B 11.94B 4.64B 57.84B 4.64B 4.54B 200B P/E 2026 *
9.37x
P/E 2027 * 8.03x
Enterprise Value 2.28B 2B 1.84B 1.71B 3.24B 217B 3.29B 22.08B 8.59B 107B 8.57B 8.39B 370B EV / Sales 2026 *
3.45x
EV / Sales 2027 * 2.9x
Free-Float
45.12%
Yield 2026 *
-
Yield 2027 * -
1 day+0.14%
1 week-6.99%
Current month-6.23%
1 month-2.26%
3 months-8.71%
6 months-24.45%
Current year-32.55%
1 week 3.46
Extreme 3.455
3.8
1 month 3.45
Extreme 3.45
4.59
Current year 2.94
Extreme 2.94
5.58
1 year 2.94
Extreme 2.94
9.94
3 years 2.94
Extreme 2.94
18
5 years 2.94
Extreme 2.94
18
10 years 2.94
Extreme 2.94
18
Manager TitleAgeSince
Chief Executive Officer 55 28/02/2026
Director of Finance/CFO 48 09/07/2025
Chief Tech/Sci/R&D Officer - 31/12/2022
Director TitleAgeSince
Chairman 56 31/12/2018
Director/Board Member 64 31/12/2018
Director/Board Member 58 31/12/2018
Date Insider Type Main position Quantity % Market Cap.
03-31Free

Chief Executive Officer

117,271 0.0355%
03-31Buy

Founder

318,000 0.0963%
03-31Sell

Founder

318,000 0.0963%
Change 5-day change 1-year change 3-year change Capi.($)
+0.14%-6.99%-62.35%-57.80% 1.23B
-1.03%+5.24%+2.94%+9.41% 50.25B
+0.83%+2.51%+423.53%+627.47% 40.39B
+1.22%+7.74%+28.15%-3.98% 34.38B
-0.53%+8.01%+27.72%+62.38% 34.4B
+1.31%-0.56%+5.12%+33.90% 26.32B
+1.05%+1.42% - - 16.64B
-3.02%+3.78%+72.35%+133.36% 16.14B
+0.32%+0.53%+14.33%+21.47% 13.71B
+3.40%+8.56%+106.02%+106.02% 13.75B
Average +0.39%+2.57%+68.65%+103.58% 24.72B
Weighted average by Cap. +0.30%+4.04%+95.65%+141.17%

Financials

2026 *2027 *
Net sales 661M 579M 533M 494M 938M 62.76B 954M 6.4B 2.49B 30.98B 2.48B 2.43B 107B 799M 699M 644M 597M 1.13B 75.83B 1.15B 7.73B 3B 37.43B 3B 2.93B 129B
Net income 165M 144M 133M 123M 234M 15.66B 238M 1.6B 620M 7.73B 619M 606M 26.71B 134M 117M 108M 100M 190M 12.72B 193M 1.3B 504M 6.28B 503M 492M 21.7B
Net Debt 1.05B 917M 845M 784M 1.49B 99.49B 1.51B 10.14B 3.94B 49.1B 3.94B 3.85B 170B 1.08B 946M 872M 808M 1.53B 103B 1.56B 10.45B 4.06B 50.62B 4.06B 3.97B 175B
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
05/07/26 US$3.460 -4.16% 622,049
02/07/26 US$3.610 +0.84% 479,403
01/07/26 US$3.580 -2.98% 883,001
30/06/26 US$3.690 -0.81% 853,939
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
3.460USD
Average target price
14.60USD
Spread / Average Target
+321.97%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALVO Stock